Zynex Stock Plunges 44% After Q3 Loss and CEO Transition

Introduction

Zynex Inc (NASDAQ: ZYXI) is a Colorado-based medical device company founded in 1996 by Thomas Sandgaard. The firm specializes in electrotherapy products for pain management, physical rehabilitation, neurological diagnostics, and non-invasive cardiac monitoring through its three subsidiaries: Zynex Medical, Zynex Monitoring Solutions, and Zynex NeuroDiagnostics.

Corporate Structure

Headquartered in Englewood, Colorado, Zynex employs approximately 501–1,000 staff across its manufacturing, R&D, and commercial divisions. Zynex Medical markets FDA-cleared TENS/IFC/NMES devices for home use, while Zynex Monitoring Solutions and Zynex NeuroDiagnostics focus on hospital-grade cardiac monitors and neurologic diagnostic equipment, respectively.

Electrotherapy by Natanael Melchor

Recent Developments and News

On December 16, 2025, Zynex filed a Form 8-K (Acc-no. 0001104659-25-121390) reporting updates under Items 1.01, 1.03, 2.04, 7.01, and 9.01, which typically cover management changes, financial highlights, and governance matters.
In the Form 10-Q for the quarter ended September 30, 2025 (filed November 17, 2025; Acc-no. 0001104659-25-113280), Zynex detailed its third-quarter results. Year-to-date revenue stood at $108.2 million, with a net loss of $73.96 million (EPS: –$2.41). Total cash was $13.26 million as of quarter-end.
Zynex announced the appointment of Steven Dyson as Chief Executive Officer effective December 2025. The company continues community engagements, sponsoring veteran events and hosting employee activities.

Financial and Strategic Analysis

• Stock Performance: On December 15, 2025, ZYXI closed at $0.37, down 44.08% for the day, with trading volume of 694,527 shares. The 52-week range is $0.38–$8.72. Market capitalization is approximately $20.2 million; enterprise value is $78.6 million.
• Valuation Metrics: Price/Sales ratio (TTM) is 0.19, Price/Book (MRQ) is 34.84, and EV/Revenue is 0.73. No meaningful P/E ratios are available due to negative earnings.
• Profitability: Trailing twelve-month net margin is –68.35%; return on assets is –27.11%. Levered free cash flow is –$2.24 million (TTM).
• Analyst Ratings: Consensus Investment Rating is “Hold” with a $6.00 target price. Subratings include Medium for Industry and Growth, High for Value, and Low for Management, Safety, and Financial Strength.

Strategically, Zynex remains focused on expanding its electrotherapy footprint and advancing products in cardiac monitoring and neurodiagnostics. Ongoing R&D investments are aimed at new device approvals and reimbursement alignment in the U.S. healthcare market.

Market Position and Industry Context

Zynex operates within the medical equipment manufacturing sector, which in 2025 continues to prioritize non-invasive therapies and remote patient monitoring. Key competitors include larger manufacturers of TENS devices and hospital-grade monitors. Zynex’s current financial metrics reflect operational challenges and execution risk, while its price-to-sales ratio may suggest potential for valuation improvement should revenue growth occur.

tl;dr

On December 16, 2025, Zynex filed an 8-K outlining governance and strategic updates following a third-quarter revenue report (ended September 30) showing $108.2 million in sales and a $73.96 million net loss. Shares declined 44.08% to $0.37 on December 15 amid liquidity concerns. CEO Steven Dyson took leadership in December. Analysts rate the stock “Hold” with a $6.00 target, noting moderate growth prospects but low financial strength. Ongoing R&D and reimbursement efforts will be critical for future performance.